Session » Vasculitis – Non-ANCA-Associated & Related Disorders Poster II (1862–1888)

Date: Tuesday, November 9, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 1864

18F-Fluorodeoxyglucose PET/MRI as an Alternative Hybrid Imaging Modality: Comparative Study in a Prospective, Longitudinal Cohort of Patients with Large-Vessel Vasculitis

8:30AM-10:30AM: Abstract Number: 1876

A Prospective Observational Cohort Study and Systematic Review of 40 Patients with Mouth and Genital Ulcers with Inflamed Cartilage (MAGIC) Syndrome

8:30AM-10:30AM: Abstract Number: 1885

Biological Therapy in Refractory Neurobehçet’s Disease. Multicenter Study of 42 Patients

8:30AM-10:30AM: Abstract Number: 1871

Characterization of Symptoms of Nasal Disease in Relapsing Polychondritis Using Patient-Reported Data

8:30AM-10:30AM: Abstract Number: 1882

Clinical Characteristics and Reliability of a Self-Reported Diagnosis of Large-Vessel Vasculitis

8:30AM-10:30AM: Abstract Number: 1862

Clonal Hematopoiesis Across the Age Spectrum in Patients with Systemic Vasculitis

8:30AM-10:30AM: Abstract Number: 1870

Comparative Study on Anti-TNF vs Tocilizumab for Treatment of Refractory Uveitic Cystoid Macular Edema Due to Behcet’s Disease: Multicenter Study of 49 Patients

8:30AM-10:30AM: Abstract Number: 1863

Consistent Efficacy with Apremilast in Men and Women to Treat Oral Ulcers Associated with Behçet’s Syndrome: Results from Phase 3 Researching Oral Apremilast Safety and Efficacy in Behçet’s Disease (RELIEF) Study

8:30AM-10:30AM: Abstract Number: 1879

Delayed Diagnosis of IgG4 Related Disease Is Associated with Worse Outcome: A Retrospective, Real-life Observational Study

8:30AM-10:30AM: Abstract Number: 1880

Description of an Internet-Based Cohort with a Self-Reported Diagnosis of Polyarteritis Nodosa

8:30AM-10:30AM: Abstract Number: 1872

Differentiating Primary Central Nervous System Vasculitis from Non-inflammatory Intracranial Vasculopathy

8:30AM-10:30AM: Abstract Number: 1887

Evidence-Based Behçet’s Disease Activity Scale (EBDA) – A New Instrument with Improved Acuity for Major Organ Disease Activity and Remission Depth Assessment

8:30AM-10:30AM: Abstract Number: 1875

Hyoscine Butylbromide Inhibits Neutrophil Cell Death Induction by Cocaine-levamisole. a Proof of Concept for the Management of Vasculopathy Induced by Cocaine-Levamisole

8:30AM-10:30AM: Abstract Number: 1865

Incidence, Prevalence, and Mortality of Chronic Periaortitis: A Population-based Study

8:30AM-10:30AM: Abstract Number: 1867

Investigating Adenosine Deaminase 2 Activity in Large Vessel Vasculitis

8:30AM-10:30AM: Abstract Number: 1883

Neuro-Behcet’s Disease: 20 Years Single Center Experience of Cyclophosphamide for Induction of Remission

8:30AM-10:30AM: Abstract Number: 1868

Neutrophil Extracellular Trap Formation in Patients with Vasculitis

8:30AM-10:30AM: Abstract Number: 1884

Real-life Data for the Use of Anti-TNF Treatment in DADA2

8:30AM-10:30AM: Abstract Number: 1881

Surgical Outcomes After Operative Procedures in Patients with Behcet’s Disease

8:30AM-10:30AM: Abstract Number: 1877

Takayasu Arteritis Patients with Tuberculosis Have Unique Clinical Characteristics

8:30AM-10:30AM: Abstract Number: 1873

The Importance of Lower Extremity Vein Wall Thickness in Patients with Behcet’s Syndrome

8:30AM-10:30AM: Abstract Number: 1869

The Role of Faecal Calprotectin in IgA Vasculitis

8:30AM-10:30AM: Abstract Number: 1878

Tocilizumab in Caucasian Patients with Takayasu Arteritis: Multicenter Study of 54 Patients

8:30AM-10:30AM: Abstract Number: 1888

Usefulness of 2019 ACR/EULAR Classification Criteria (AECC) for IgG4-Related Disease Differs Between Clinical Phenotypes of IgG4-RD

8:30AM-10:30AM: Abstract Number: 1874

Using 18F-fluorodeoxyglucose Positron Emission Tomography to Standardize Clinical Trial Recruitment in Takayasu’s Arteritis

8:30AM-10:30AM: Abstract Number: 1886

Validation of Angiographic Patterns of Disease in a Turkish Cohort of Patients with Takayasu’s Arteritis

8:30AM-10:30AM: Abstract Number: 1866

Vasculitis in Patients with Sarcoidosis: A Single-Institution Case Series of 17 Patients

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].